Document is current
Any future updates will be listed below
-
Authors
Agersnap, Mikkel Askjær https://orcid.org/0000-0002-5827-5870
Sonne, Kim
Knudsen, Kim Mark
Knudsen, Carsten Boye
Berner-Hansen, Mark
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03279302 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects
https://doi.org/10.1007/s40261-022-01210-1
- License Information
-
More Information
Article History
Accepted: 2 October 2022
First Online: 2 November 2022
Declarations
:
: The study was funded by Zealand Pharma.
: Mikkel Askjær Agersnap, Kim Mark Knudsen, Carsten Boye Knudsen and Mark Berner-Hansen are employed at Zealand Pharma. Kim Sonne was formerly employed at Zealand Pharma.
: Prior to the start of the study, the study protocol, protocol amendment, informed consent form and study recruitment materials were reviewed and approved by the applicable institutional review board (Schulman Associates Institutional Review Board, Cincinnati, OH, USA; approval number 201704938).
: All study participants gave written informed consent prior to undergoing any study-related procedures or assessments.
: Not applicable.
: Data will be provided upon request to the corresponding author.
: The code will be provided upon request to the corresponding author.
: MAA, KS, CBK and MBH was scientifically responsible for the study, and KMK was responsible for the statistical considerations and analyses. CBK and KMK take full responsibility for the verification of the underlying data. All authors provided input to the manuscript and edited and approved the manuscript for submission. All authors had full access to the clinical study report and associated documents.
